https://scholars.lib.ntu.edu.tw/handle/123456789/586036
標題: | The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials | 作者: | Lin, Donna Shu-Han JEN-KUANG LEE CHI-SHENG HUNG WEN-JONE CHEN |
關鍵字: | CVOT; Cardiovascular outcome trial; Composite renal outcome; DPP4; Meta-analysis; SGLT-2 | 公開日期: | 18-九月-2021 | 來源出版物: | Diabetologia | 摘要: | Several cardiovascular outcome trials on sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been released recently, including trials enrolling patients with congestive heart failure (CHF) and chronic kidney disease (CKD). Comparisons of the efficacy and safety of SGLT2i, glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) thus require an update. Assessments in patient subgroups, i.e., as stratified by age or the presence of CHF, CKD or atherosclerotic cardiovascular disease (ASCVD), are also currently lacking. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/586036 | ISSN: | 0012186X | DOI: | 10.1007/s00125-021-05529-w | SDG/關鍵字: | dipeptidyl peptidase IV inhibitor; glucagon like peptide 1 receptor agonist; sodium glucose cotransporter 2 inhibitor; age; all cause mortality; cardiovascular mortality; cardiovascular risk; chronic kidney failure; clinical outcome; congestive heart fail |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。